摘要
目的探讨血必净注射液对重症脓毒症患者外周血单核细胞人白细胞抗原DR(HLA-DR)表达的影响及其临床意义。方法 43例重症脓毒症患者分成对照组(21例)和治疗组(22例)。对照组患者给予常规救治,治疗组患者则在常规救治的基础上早期加用血必净注射液治疗。采用流式细胞分析技术测定患者在治疗前和治疗后第5d两个时间点的外周血单核细胞HLA-DR表达率,并使用急性生理学与慢性健康状况评分系统(APACHE)Ⅱ对患者的病情进行评估。结果在治疗后第5d,两组患者外周血CD14+单核细胞HLA-DR表达率均较治疗前明显升高,差异有统计学意义(P均<0.05)。其中,治疗组患者的外周血CD14+单核细胞HLA-DR表达率在治疗后第5d时升高更为明显,与对照组比较,差异有统计学意义。此外,治疗后第5d,治疗组患者的APACHEⅡ评分较对照组明显降低,差异有统计学意义(P<0.05)。结论对于重症脓毒症患者,在常规救治的基础上早期使用血必净注射液能较快促使患者外周血CD14+单核细胞HLA-DR表达率较快地回升,减轻免疫抑制,具有较强的免疫调理作用。
Objective To investigate the effect and clinical value of Xuebijing injection on peripheral monocyte human leukocyte antigen D-related （HLA-DR） expression in patients with severe sepsis. Methods Forty-three patients with severe sepsis were divided into a control group （21 cases） and a treatment group （22 cases）. Besides regular treatment for the two groups, the treatment group was received Xuebijing injection on the early stage. The HLA-DR expression was detected by flow cytometry at two time points （pre-treatment and 5th d after treatment） and the desease conditions were monitored by acute physiology and chronic health evaluation （APACHE） I1 scoring system in both the two groups. Results The CD14＋ monocyte HLA-DR expression in all the patients was markedly increased, especially the treatment group, on 5th d after treatment （all P〈0.05）. Furthermore, the APACHE 11 score in the treatment group was increased obviously compared with the control group （P〈0.05）. Conclusion For the patients with severe sepsis, early using the Xuebijing injection after regular treatment can increase the CD14＋ monocyte HLA-DR expression and lessen immunity depression.
出处
《中华危重症医学杂志（电子版）》
CAS
2010年第5期8-10,共3页
Chinese Journal of Critical Care Medicine:Electronic Edition
